For many years.

For many years, sympathomimetic bronchodilator aerosols have provided the chiefly popular form of therapy for chronic bronchospastic diseases and for acute exacerbations. During the last 25 years, occasional reports of adverse general intents resulting from these drugs have l to suggestions that they should not be used in asthma. This repetitive bear upon has become more persistent in the last hardly any years, and well-publicized reports prompt that patients receiving regular sympathomimetic aerosol therapy, may stand bronchospastic relapses and progressive deterioration in airflow when compared with patients who use their aerosol bronchodilators sparingly. Now, a discreet review by Taylor and Sears in this issue (see page 552) catalogues the evidence that allows them to make an indictment of [beta]-adrenergic agonists. These experienced investigators propose that regular or frequent use of [beta]-agonists is the one and the other harmful and unnecessary in asthma; however, their studies appear to endorse prn or pro re nata, therapy, equal though this provides patients with the option to use the prescribed aerosol regularly several times a day for relief of perceived symptoms of bronchospasm.

Part of the case against [beta]-agonists is based forward the contention that the progressive worldwide increase in overall usage of these agents has been accompanied at an apparent increase in the severity of asthma and an escalation in mortality for the past 15 years.[1] It is important to realize that other unsalable articles - including steroids - could be held equally indictable, since their use has also increased in the period that asthma issue has allegedly worsened. Furthermore, in spite of the unfavorable reports in succession selected groups of patients, there appears to have been no clear correlation between routine bronchodilator use and deterioration in the repress of either asthma or chronic obstructive pulmonary disease (COPD) in the large population of patients who rely solely upon routine regular use of inhaled sympathomimetics. It clearly is accepted and advised that those asthmatics who cause to grow exacerbations while using regular doses of a [beta]-agonist aerosol can be wait fored to respond in an unforeseen occasion room to inhalation of a great deal larger dosages of the same [beta]-agonist.[2] This implies that deterioration come to one's minds as a consequence of inadequate [beta]-agonist dosing rather than because of excessive use, as improvement can happen even if other classes of unsalable articles are not given.

It is probable that greatest in number experienced clinicians will agree with Woolcock[3] who points public "Huge amounts of salbutamol (albuterol) have been used in the last 20 years and there is little objective evidence that the use of the unsalable article has caused any problem." This endorsement of albuterol could be readily stretch outed to all commonly used aerosol bronchodilators, with the possible exception of fenoterol.

modern studies that report an adverse issue from routine, regular bronchodilator use have placed great emphasis forward the findings of increases in hyperreactivity or decreases in spirometric touchstones of pulmonary function. These laboratory changes, however, have generally been small, and their significance cannot readily be translated to the clinical situation.[4] Moreover, it should be kept in mind that anti-inflammatory put drugs intos that do reduce hyperreactivity have not been shown in long-term studies to be ideal for all asthma patients (including the typical noncompliant ones) nor are they of value in mostly patients with COPD. In patients with asthma these medicines must be used continuously; relapse can meet the eye when treatment is stopped, deliberately or otherwise, plane after years of therapy.5

It is reasonable to accept that there must be about relevance in the report of adverse efficiencys of 2-agonists. Obviously, all remedys however useful they are, carry the potential for dangerous replications and selected patient groups will display greater susceptibility to toxicity. It, however, would be improper to condemn the current use of [beta]-agonists upon the basis of limited studies and a selective examination of the literature. Thus, these physics can be safe and valuable, although their misuse, as is the case with almost any put drugs into can be harmful. We are reminded of the of long date definition of a drug as "a poison that happens to have useful side effects"

Patients with asthma whose therapy is based forward regular use of anti-inflammatory unsalable articles will still require [beta]-agonists for liberate or for treating exacerbations, just as those who use regular [beta.sub.2]-agonists will require steroid therapy to manage their exacerbations. No individual would dream of banning aerosol steroids, cromolyn or nedocromil in reaction to the used by all experience that patients do deteriorate from time to time onward these drugs and then require massive doses of [beta]-agonists to subdue the detrimental results of their regular anti-inflammatory therapy. wherefore would Taylor and Sears want to withhold [beta.sub.2]-agonists when there is vast evidence to put in mind of that their regular use accompanied from supplementary prescribing of an anti-inflammatory agent constitutes the best therapy for mostly severe asthmatic conditions and possibly for a proportion of patients with COPD?

...